Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD trimmed its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 4.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,218,326 shares of the biopharmaceutical company's stock after selling 52,195 shares during the quarter. Price T Rowe Associates Inc. MD owned 0.96% of Halozyme Therapeutics worth $58,249,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Heck Capital Advisors LLC acquired a new position in shares of Halozyme Therapeutics during the fourth quarter valued at about $29,000. CBIZ Investment Advisory Services LLC purchased a new stake in Halozyme Therapeutics during the 4th quarter worth approximately $29,000. Smartleaf Asset Management LLC increased its stake in Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 197 shares in the last quarter. Venturi Wealth Management LLC purchased a new position in shares of Halozyme Therapeutics in the fourth quarter worth $69,000. Finally, Parkside Financial Bank & Trust lifted its stake in shares of Halozyme Therapeutics by 21.8% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 322 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on HALO shares. Piper Sandler raised their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research note on Friday, January 10th. HC Wainwright reaffirmed a "buy" rating and set a $72.00 target price on shares of Halozyme Therapeutics in a report on Friday, April 25th. JPMorgan Chase & Co. increased their price target on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. Benchmark restated a "buy" rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Finally, Wells Fargo & Company dropped their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $62.89.

Halozyme Therapeutics Stock Performance

HALO stock traded up $1.16 during midday trading on Friday, hitting $61.19. 1,098,414 shares of the stock traded hands, compared to its average volume of 1,443,747. Halozyme Therapeutics, Inc. has a 1-year low of $40.19 and a 1-year high of $66.00. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The stock's fifty day simple moving average is $60.79 and its 200-day simple moving average is $55.41. The firm has a market cap of $7.56 billion, a P/E ratio of 17.84, a PEG ratio of 0.42 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. On average, analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the transaction, the senior vice president now owns 185,453 shares in the company, valued at $10,765,546.65. This trade represents a 5.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jeffrey William Henderson sold 4,497 shares of the business's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $60.37, for a total value of $271,483.89. Following the sale, the director now owns 28,611 shares of the company's stock, valued at $1,727,246.07. The trade was a 13.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 26,697 shares of company stock valued at $1,558,052. 2.40% of the stock is owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.